Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 10;12(11):2572.
doi: 10.3390/biomedicines12112572.

Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases

Zsolt Vastag  1   2   3 , Emanuela Tudorache  1   4 , Daniel Traila  1   4 , Ovidiu Fira-Mladinescu  1   4 , Monica Steluta Marc  1   4 , Cristian Oancea  1   4 , Elena Cecilia Rosca  5   6
Affiliations
Review

Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases

Zsolt Vastag et al. Biomedicines. .

Abstract

Patients with interstitial lung diseases (ILDs) associate a large variety of comorbidities that have a significant impact on their clinical outcomes and survival. Among these comorbidities is neurological impairment. This review highlights what is known about the cognitive function, central nervous system (CNS), depression, and anxiety in patients with specific forms of fibrosing ILDs, such as idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, connective tissue diseases, etc. The most common pathogenic mechanisms for neurocognitive dysfunction as well as the screening methods and tools for their identification are also described in this review.

Keywords: anxiety; cognitive impairment; connective tissue diseases; depression; idiopathic pulmonary fibrosis; sarcoidosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The pathogenesis of neurological damage in fibrosing ILD.
See this image and copyright information in PMC

References

    1. Selman M., Pardo A., Wells A.U. Usual interstitial pneumonia as a stand-alone diagnostic entity: The case for a paradigm shift? Lancet Respir. Med. 2023;11:188–196. doi: 10.1016/S2213-2600(22)00475-1. - DOI - PubMed
    1. Brown K.K., Martinez F.J., Walsh S.L.F., Thannickal V.J., Prasse A., Schlenker-Herceg R., Goeldner R.G., Clerisme-Beaty E., Tetzlaff K., Cottin V., et al. The natural history of progressive fibrosing interstitial lung diseases. Eur. Respir. J. 2020;55:2000085. doi: 10.1183/13993003.00085-2020. - DOI - PMC - PubMed
    1. Raghu G., Remy-Jardin M., Richeldi L., Thomson C.C., Inoue Y., Johkoh T., Kreuter M., Lynch D.A., Maher T.M., Martinez F.J., et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022;205:E18–E47. doi: 10.1164/rccm.202202-0399ST. - DOI - PMC - PubMed
    1. Margaritopoulos G.A., Antoniou K.M., Wells A.U. Comorbidities in interstitial lung diseases. Eur. Respir. Rev. 2017;26:160027. doi: 10.1183/16000617.0027-2016. - DOI - PMC - PubMed
    1. Jo H.E., Randhawa S., Corte T.J., Moodley Y. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs Aging. 2016;33:321–334. doi: 10.1007/s40266-016-0366-1. - DOI - PubMed

LinkOut - more resources